Genetic Variants Predict Outcomes After t-PA Treatment

This article originally appeared here.
Share this content:
Genetic Variants Predict Outcomes After t-PA Treatment
Genetic Variants Predict Outcomes After t-PA Treatment

(HealthDay News) – Two genetic variants have been identified that are associated with hemorrhagic transformation (HT) and mortality rates after infusion of tissue plasminogen activator (t-PA) in patients with acute ischemic stroke, according to research published online June 9 in the Annals of Neurology.

Alberto del Rio-Espinola, PhD, of the Vall d'Hebrón Hospital in Barcelona, Spain, and colleagues conducted a prospective study using SNPlex to genotype 140 single nucleotide polymorphisms (SNPs) from 97 candidate genes in three patient cohorts. The cohorts included 1,172 patients who were treated with t-PA after acute ischemic stroke. Of these patients, 20.9 percent developed HT and 10.6 percent died. A clinical-genetic model was generated to predict t-PA response.

In replication analysis, the researchers found that the SNP rs669 in alpha-2-macroglobulin (A2M) correlated with HT and withstood Bonferroni correction; and rs1801020 of F12 correlated with in-hospital death. A logistic regression-based predictive model significantly predicted both HT occurrence and in-hospital mortality, and was validated in an independent cohort. The rs669 SNP was associated with modified A2M serum levels at baseline and after t-PA infusion, but did not affect mRNA expression or protein structure. The rs1801020 SNP was associated with altered factor XII activity both before and after t-PA treatment.

"The calculation of HT risk could allow clinicians to individualize fibrinolytic treatment, increasing the therapeutic window for low-risk patients, and more accurately define t-PA risk versus benefit in high-risk individuals," the authors write. "This study might be the first step in the development of personalized medicine and new coadjuvant treatments for t-PA."

Abstract
Full Text (subscription or payment may be required)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs